Study of elranatamab for newly diagnosed AL amyloidosis
Part of Cancer, Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests a new targeted medicine called elranatamab for people newly diagnosed with AL amyloidosis, a condition where abnormal proteins build up in organs. It aims to see if this treatment can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be newly diagnosed with AL amyloidosis and have not had any previous treatment for it.
- You must be 18 years or older.
- Your heart and other organs must be functioning well enough, as determined by your doctor.
- You must be willing to have regular bone marrow biopsies and other study procedures.
- You must agree to use effective birth control during the study and for 90 days after the last dose, if applicable.
- You cannot have certain other serious medical conditions, like uncontrolled heart rhythm problems or active infections like HIV or hepatitis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (teclistamab and daratumumab) for people with AL amyloidosis who have not had prior treatment. The goal is to see if this combination can safely and effectively reduce the abnormal protein deposits in organs.
This trial tests a combination of four drugs (belantamab mafodotin, cyclophosphamide, bortezomib, and dexamethasone) for people newly diagnosed with AL amyloidosis who cannot have a stem cell transplant. The goal is to see if this combination is safe and effective at stopping the abnormal proteins from damaging your organs.
This trial tests a drug called elranatamab for people with AL amyloidosis whose disease has come back or is not responding to treatment. The goal is to see if it can help control the disease.
This trial tests a new bispecific antibody treatment for people newly diagnosed with AL amyloidosis. The drug targets BCMA on myeloma cells and CD3 on immune cells to help your body fight the disease.
This trial tests a combination of two new drugs, sonrotoclax and a BCMA bispecific antibody, for people newly diagnosed with AL amyloidosis. The treatment aims to target and destroy the abnormal cells that cause the disease, potentially improving outcomes.
This trial tests a new drug (a bispecific antibody) for people newly diagnosed with AL amyloidosis, a condition where abnormal proteins build up and damage organs. The drug aims to target and clear these abnormal cells to help reduce organ damage.
Hear when a new Amyloid Light-chain Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.